Matritech has appointed Richard Sandberg, a former chairman of DNA diagnostics company Lifecodes, to the company’s board of directors. Sandberg, who previously served on Matritech’s board from 1999 to June 2002, has returned after a hiatus due to personal reasons. Sandberg has also held a variety of management positions, including chairman and CEO, for Dianon Systems, an oncology marketing and database company. Newton, Mass.-based Matritech uses proteomics to develop diagnostics for the early detection of cancer.
Millennium Pharmaceuticals has hired 10 new directors across its business and scientific teams. Joining the company with positions in molecular medicine are: Ronnen Roubenoff, senior director, molecular medicine; Julie Lekstrom-Himes, director, molecular medicine; and Gerald Linette, director, molecular medicine. In other scientific areas, Matthew Pollman has joined Millennium as director, cardiovascular biology; Chris Webster as director, regulatory affairs; Shimoga Prakash as director, science/research; and Michael Cooper as senior director, clinical research.
Brent Boeckmann has joined the Indiana Proteomics Consortium as vice president for business development. A former investment banker for Anderson Worldwide in London, Boeckmann will be responsible for establishing new stand-alone ventures or partnerships based on the technology developed by the consortium.
Francois Pons has joined Grenoble, France-based Genome Express as director of business development, in charge of promoting business relationships around the company’s genomics and proteomics technology. Prior to joining Genome Express, Pons served as director of business development and scientific communication at the Centre d’Immunologies Pierre Fabre in Saint Julien en Genevois, France. Pons has also worked for Baxter Healthcare France in strategic marketing.
Signature BioScience has appointed Robert Zimmerman chief operating officer and executive vice president for R&D, and Mary Ann Rafferty vice president for talent acquisition and development. Zimmerman, who most recently served as vice president for biotechnology research at Bayer, will be responsible for scaling up Signature’s drug discovery platform, and guiding the company’s oncology product pipeline. Rafferty will be responsible for recruiting and maintaining Signature’s human resources.